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Introduction
Esophageal and gastric cancers continue to pose a 
significant burden of morbidity and mortality globally. In 
2012, it was estimated that gastric cancer was the fifth most 
common cancer worldwide, and the third leading cause 
of cancer death (1). Esophageal cancer, while incidentally 
less common than gastric cancer, has a striking mortality 
rate, placing it as the sixth leading cause of cancer related 
deaths worldwide (1). Furthermore, it has been known 
for the past few decades that the incidence of esophageal 
adenocarcinoma has substantially increased, mirroring the 
prevalence of gastroesophageal reflux disease and Barrett’s 
esophagus, particularly in North American and Europe (2,3). 
While important advances have been made in the early 
detection and treatment of esophageal and gastric cancers, 
the majority of patients continue to present with clinical 
evidence of regional or distant disease (4). While treatment 
for esophageal and gastric cancers has traditionally 
involved combinations of aggressive surgical resection, 
chemotherapy, and radiotherapy, the percent of patients 
achieving 5-year survival remains under 20% (4). Because of 
the intractable nature of these diseases, it is not surprising 
that attention has turned towards biologic therapies to offer 
a more tailored, and potentially effective, treatment option. 
This review will examine biologic therapies that now have 
established efficacy in esophageal and gastric cancers, as 
well as those that are currently under investigation and hold 
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potential benefit (Table 1). 
Human epidermal growth factor receptor 2 
(HER2) targeted therapies
Initially discovered as an overexpressed transmembrane 
tyrosine kinase receptor in approximately one-third of 
breast cancer patients that was associated with decreased 
survival, HER2, or c-erb-2, proto-oncogene quickly became 
an important tumor marker and target for therapy (5). 
Given the fact that HER2 is constitutively expressed on 
many different epithelial cell types, studies sought to 
understand its prevalence in other malignancies, including 
esophageal and gastric cancers (6). It is estimated that 
approximately 30% of gastroesophageal adenocarcinomas 
and 20% of gastric cancers overexpress HER2, and early 
studies showed wide variability of overexpression depending 
on the specific method of testing (7,8). Rates for HER2 
overexpression in squamous cell carcinoma of the esophagus 
has been found to range from 5% to almost 40% (9,10).
Once HER2 was found to be overexpressed in subgroups 
of esophageal, esophagogastric, and gastric cancer patients, 
the next question was whether this oncogene was associated 
with poorer survival rates as seen in breast cancer. Early 
institutional studies evaluating HER2 overexpression and 
long-term overall survival were known for conflicting 
findings (11,12). In a meta-analysis of operable esophageal 
cancer patients, it was found that among high-quality 
analyses, esophageal adenocarcinoma patients with 
overexpression of HER2 [most commonly defined in early 
reports as immunohistochemistry (IHC), ≥2] had poorer 
5-year all-cause mortality (OR 1.9; 95% CI, 1.2–3.2; 
P=0.001) (13). This increased rate of 5-year mortality was 
also detected for squamous cell esophageal carcinoma (OR 
2.9; 95% CI, 1.3–6.2; P=0.006) (13). For gastric cancers, 
previous work has demonstrated that HER2 overexpression 
ranges from 8–20% (with slightly higher rates for HER3 
and HER4), although correlation between expression 
of the HER2 subtypes has been demonstrated (14,15). 
Amplification in gastric cancer has been found to be 
strongly associated with intestinal type adenocarcinoma 
and significantly reduced overall survival (14,15). Current 
NCCN guidelines recommend that patients with inoperable 
locally advanced, recurrent, or metastatic adenocarcinomas 
of the esophagus, esophagogastric junction, or stomach be 
considered for tailored therapy in cases of 3+ overexpression 
by IHC or fluorescence in situ hybridization (FISH) 
positive (HER2:CEP17 ratio ≥2), and patients that are 2+ 
be additionally examined by FISH (16).
Trastuzumab
After the emergence of trastuzumab as a standard of care 
for breast cancer patients with HER2 overexpression due 
to successes in improving overall survival among those with 
metastatic disease, there was great interest to evaluate its use 
among other tumor sites (17). Trastuzumab is a monoclonal 
antibody specific for HER2 that prevents activation of the 
intracellular kinase activity, with described mechanisms 
including prevention of HER2 receptor dimerization, 
endocytic destruction of the receptor, decreased shedding 
of the extracellular domain, and increased cell-mediated 
Table 1 Potential biologic targets in esophageal, esophagogastric, and gastric malignancies, and the agents that have been evaluated to date
Biologic target Targeted agents evaluated for esophageal, EGJ, and gastric malignancies
HER-2 Trastuzumab approved in 1st-line;
Negative studies with lapatinib and T-DM1 (trastuzumab emtansine) in 2nd-line;
Pertuzumab remains under investigation (JACOB trial, TRAP trial)
EGFR Multiple negative studies with cetuximab and panitumumab in a variety of clinical settings
VEGF and VEGFR Ramucirumab approved in 2nd-line;
Negative 1st-line studies with ramucirumab, ziv-aflibercept and bevacizumab;
Positive phase III study of apatinib in the refractory setting
c-MET Negative 1st-line studies with foretinib, onartuzumab, and rilotumumab
mTOR Negative 2nd-line study with everolimus
PD-1 Pembrolizumab and nivolumab with promising phase I/II trials, need to be evaluated with phase III study
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cytotoxicity (18). 
From 2005 to 2009, the Trastuzumab for Gastric Cancer 
(ToGA) randomized controlled trial evaluated the safety and 
clinical efficacy of this agent for locally advanced, recurrent 
or metastatic adenocarcinoma of the gastroesophageal 
junction or stomach (19). For study entry, patients’ tumors 
were considered to overexpress HER2 if they were scored as 
3+ on IHC or were FISH positive (HER2/CEP17 ratio >2). 
All patients received chemotherapy consisting of either 
capecitabine plus cisplatin or fluorouracil plus cisplatin 
every 3 weeks for six cycles, with those being randomized to 
the study treatment also receiving concurrent trastuzumab. 
Patients receiving trastuzumab with chemotherapy 
did have a significant improvement in median overall 
survival compared to the chemotherapy only arm (13.8 vs. 
11.1 months), with no difference in grade 3 or 4 adverse 
events. On exploratory analyses, this improvement in 
overall survival was even more pronounced among patients 
with IHC 3+ or IHC 2+ with positive FISH (16.0 vs. 
11.8 months). Additionally, patients in the trastuzumab 
and chemotherapy arm experienced longer progression-
free survival (6.7 vs. 5.5 months) and higher rates of overall 
tumor response (47% vs. 35%). This trial established 
trastuzumab as a standard of care agent for patients with 
esophagogastric/gastric adenocarcinoma with HER2 
overexpression. 
A modification to enhance the effect of HER2 targeted 
therapy included the development of trastuzumab 
emtansine, an antibody-drug conjugate. Trastuzumab binds 
the HER2 receptor as previously described and emtansine 
(also called DM1) is internalized and inhibits cell division 
by binding to tublin, thereby inhibiting microtubule 
polymerization. This agent was evaluated in the GATSBY 
randomized controlled trial comparing trastuzumab 
emtansine with either paclitaxel or docetaxel versus a taxane 
only in patients with locally advanced/metastatic HER2 
positive gastric or gastroesophageal cancer that had shown 
progression on first line fluoropyrimidine and platinum 
therapy (20). Of note, the majority of the approximately 
400 patients randomized in this trial had received prior 
HER2 targeted therapy (77%). Ultimately, the novel 
combination of trastuzumab with emtansine did not result 
in improvements in overall survival compared to taxane 
therapy (7.9 vs. 8.6 months, P=0.86) or median progression-
free survival (2.7 vs. 2.9 months, P=0.31). 
As a substantial proportion of patients receive neoadjuvant 
chemoradiation therapy prior to esophagectomy for locally 
advanced disease, a logical extension of this neoadjuvant 
approach was to add concurrent trastuzumab to standard 
chemoradiation to the neoadjuvant therapy of patients with 
HER2 overexpressing tumors. RTOG 1010 is a phase III 
trial evaluating the addition of trastuzumab to neoadjuvant 
chemoradiation (paclitaxel and carboplatin with 50.4 Gy 
at 1.8 Gy/fraction) followed by surgery for esophageal or 
esophagogastric adenocarcinoma (21). Following recovery 
from esophagectomy, patients will continue to receive 
trastuzumab every 3 weeks, for 13 additional doses as 
maintenance therapy. Currently this multicenter trial has 
met accrual targets and results are pending. 
Lapatinib 
While patients with HER2 overexpression experienced 
a significant survival benefit with trastuzumab, the 
search for additional HER2 targets with more durable 
effects continued. One such endeavor was the Lapatinib 
Optimization Study in HER2-Positive Gastric Cancer 
(LOGiC) trial, a phase III randomized controlled study to 
evaluate clinical response of the first oral tyrosine kinase 
inhibitor of both HER2 and epidermal growth factor 
receptor (EGFR) in addition to capecitabine and oxaliplatin 
in patients with unresectable esophageal, gastroesophageal, 
or gastric adenocarcinoma (22). While there was an 
improvement in the response rate, no significant difference 
was detected in median overall survival. On subgroup 
analysis, while there was no difference in the mortality 
hazard for the lapatinib arm based on HER2 IHC status, 
significant improvements were seen in survival for patients 
under 60 years of age and in Asia. Lapatinib was also 
evaluated as a second line therapy in addition to weekly 
paclitaxel (TyTAN trial) in Asian patients with disease 
progression following gastric cancer therapy with HER2 
overexpression (23). Again, while response rates were 
improved, there was no significant difference found in 
progression-free survival or overall survival. These negative 
studies have distinguished gastroesophageal cancers from 
breast cancers where these approaches yielded improved 
outcomes for patients. Additionally, in breast cancer, HER2 
treatment is continued beyond tumor progression with first-
line therapy; this strategy has not been proven successful in 
treating gastroesophageal cancers.
Pertuzumab
Recently, pertuzumab has evolved as another possible 
adjunct therapy for HER2 overexpressing malignancies. 
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Pertuzumab binds to a different epitope of the HER2 
extracellular domain, ultimately preventing dimerization 
with other receptors in the HER family, in addition to the 
stimulation of cell-mediated cytotoxicity that trastuzumab 
was known to cause (24). A randomized controlled trial in 
patients with HER2 positive metastatic breast cancer which 
compared pertuzumab with trastuzumab to trastuzumab 
alone (with both arms receiving docetaxel) found that 
patients in the pertuzumab and trastuzumab arm had 
significantly longer median progression-free survival with 
similar safety profiles (25). Work evaluating pertuzumab 
for esophageal and gastric cancer patients is also underway. 
A phase IIA trial examining administration of pertuzumab 
in addition to trastuzumab, capecitabine, and cisplatin in 
patients with locally advanced, inoperable, or metastatic 
HER2 positive adenocarcinoma of the gastroesophageal 
junction or stomach (JOSHUA) established dosing 
parameters and established the safety profile for a phase III 
evaluation (JACOB), which is currently ongoing at over 
190 study centers (26,27). This agent is additionally being 
evaluated in a novel neoadjuvant regimen: the TRAP trial 
(Study of Chemoradiation, Trastuzumab, and Pertuzumab 
in Resectable HER2+ Esophageal Carcinoma) which is 
seeking to establish the feasibility of this multimodality 
neoadjuvant regimen and its impact on pathologic response, 
surgical margins, and postoperative complications (28).
HER1/EGFR targeted therapies
Gene amplification and overexpression of EGFR (or HER1) 
has also been documented in several malignancies including 
esophageal, esophagogastric, and gastric tumors. EGFR is a 
transmembrane protein that also has tyrosine kinase activity 
in the presence of ligands such as epidermal growth factor 
and transforming growth factor-α (29). Previous work has 
demonstrated that increased EGFR expression (2+ or 3+) 
is present in over 30% of esophageal and esophagogastric 
adenocarcinomas, and was associated with higher pathologic 
T, N, and M stage (30). In esophageal squamous cell cancer, 
even higher rates of EGFR overexpression have been 
documented, with some studies exceeding 70%, and have 
also been correlated with more advanced pathologic stages 
and poorer overall survival (31,32).
Cetuximab
Cetuximab, a chimeric monoclonal antibody targeted against 
EGFR, had shown efficacy in certain groups of metastatic 
head and neck, colon, and lung cancers and was eventually 
tested in patients with esophageal and gastric malignancies 
(33-35). The EXPAND trial evaluated cetuximab in the 
setting of capecitabine and cisplatin for patients with 
locally advanced or metastatic adenocarcinoma of the 
gastroesophageal junction or stomach, at over 100 sites in 
25 countries (36). Unfortunately, there was no significant 
improvement in progression-free survival, and a higher rate 
of grade 3–4 adverse events in patients receiving cetuximab 
compared to those receiving capecitabine and cisplatin alone. 
Panitumumab
The REAL3 phase III trial (epirubicin, oxaliplatin, and 
capecitabine with or without panitumumab) which evaluated 
an alternate EGFR inhibitor in patients with locally advanced 
inoperable or metastatic esophageal cancer (without 
molecular testing) actually found an increased mortality 
hazard among patients in the panitumumab arm (n=254) (37).
However, questions remained if there may be a benefit 
of EGFR inhibitors to select patient populations. For 
example, it is known that radiation therapy can increase 
EGFR expression in tumors, as well as increase the TGFα 
activation of the receptor, so recent phase II and phase III 
trials have sought to evaluate the effect of EGFR inhibitors 
during concurrent radiation therapy, as a means to improve 
local control and response rates (38). However, a phase 
II trial of preoperative chemoradiation with concurrent 
panitumumab in patients with resectable esophageal cancer 
(the PACT study) did not improve the pathologic complete 
response (pCR) rate past the pre-defined goal of 40% (39). 
Similarly, ACOSOG Z4051, which was a phase II trial 
evaluating a neoadjuvant regimen of docetaxel, cisplatin, 
panitumumab, and 50.4 Gy in 1.8 Gy/fraction, followed by 
esophagectomy, achieved a pCR rate of 33.3%, but did not 
reach the primary objective of a pCR rate of ≥35% (40). 
Additionally, almost half of patients experienced a toxicity 
of ≥4. Given EGFR inhibitors’ lack of efficacy, and evidence 
of possible harm in some patient groups, this family of 
agents has largely been abandoned for esophageal and 
gastric malignancies until improved techniques to select 
appropriate patients that may benefit from these agents can 
be identified and validated. 
Vascular endothelial growth factor (VEGF) 
targeted therapies
Similar to other tumor types, the pathways of neoangiogenesis 
422 Samson and Lockhart. Biologics in esophageal, EGJ, and gastric malignancies
© Journal of Gastrointestinal Oncology. All rights reserved. J Gastrointest Oncol 2017;8(3):418-429jgo.amegroups.com
have been considered as potential targets in esophageal and 
gastric cancer. The VEGF family has long been documented 
to regulate tumor angiogenesis and lymphangiogenesis. 
However, it has been challenging to determine which specific 
tumor profiles may benefit the most from VEGF inhibitors. 
While not routinely used in most clinical practices, possible 
surrogates of VEGF activity (and potential markers of 
response to VEGF inhibitors) have included high tumor 
microvessel count (MVC), high proliferating cell nuclear 
antigen (PCNA), VEGF:basic fibroblastic growth factor 
(bFGF) ratio, as well as VEGF polymorphism subtyping (41). 
However, given the fact that activity of the VEGF family 
nearly ubiquitously stimulates angiogenesis to promote 
tumor growth, survival, and eventually migration, VEGF 
inhibitors have been assessed in many tumor types in the 
absence of specific tumor marker categorization. 
Bevacizumab
One of the agents investigated in this family was 
bevacizumab, a VEGF-A inhibitor. The AVAGAST phase 
III trial evaluated bevacizumab in combination with cisplatin 
and capecitabine (or fluorouracil) for patients with previously 
untreated locally advanced or metastatic adenocarcinoma 
of the gastroesophageal junction or stomach (42). While 
the addition of bevacizumab to first-line chemotherapy did 
not result in improvements in overall survival, a significant 
improvement in progression-free survival (6.7 vs. 5.3 months) 
and overall response rate (46% vs. 37.4%) was detected. 
On subgroup analysis, significant decreases in overall 
mortality hazard was detected for patients from North or 
South America (but not for European or Asian patients) 
and for those patients with locally advanced disease (but not 
with metastatic disease). A latter study of blood and tissue 
markers from patients in the AVAGAST trial demonstrated 
that patients with higher baseline levels of VEGF-A 
and lower levels of neurophilin-1 (a transmembrane 
glycoprotein) were more sensitive to bevacizumab treatment 
with significant improvements in overall survival (43). Of 
note, this finding still showed geographic variation, with 
Asian patients not demonstrating the same benefit with 
bevacizumab, despite high VEGF-A levels. 
Ramucirumab
Ramucirumab, a VEGFR-2 inhibitor that prevents VEGF 
binding in endothelial cells, was assessed as a second 
line therapy after platinum or fluoropyrimidine therapy 
for recurrent or metastatic gastroesophageal junction 
or gastric cancer (REGARD) (44). In this multicenter 
trial, improvements in median overall survival did reach 
significance (5.2 months for the ramucirumab arm vs. 
3.8 months in the placebo arm), as did the improvement 
in median progression free survival (2.1 vs. 1.3 months, 
respectively). Ramucirumab was further evaluated with 
concurrent paclitaxel in locally advanced or metastatic 
esophagogastric or gastric adenocarcinoma with evidence 
of disease progression after first line chemotherapy 
(platinum and fluoropyrimidine doublet, with or without 
anthracycline), in the phase III RAINBOW trial (45). 
Compared to the paclitaxel only arm, patients that also 
received ramucirumab experienced longer median overall 
survival (9.6 vs. 7.4 months). Of note, patients in the 
combined ramucirumab and paclitaxel arm did experience 
higher rates of selected Grade 3 or higher adverse events 
including neutropenia, leucopenia, and hypertension. 
However, based on these findings, ramucirumab is now 
a preferred second-line therapy for metastatic or locally 
advanced esophagogastric or gastric adenocarcinoma 
(category 1 recommendation from the NCCN) and 
esophageal adenocarcinoma (category 2A) (16). Evaluation 
of ramucirumab as a first-line agent to date has not 
been endorsed. A multicenter phase II trial evaluating 
ramucirumab with leucovorin, fluorouracil, oxaliplatin 
(FOLFOX) in patients with previously untreated locally 
advanced or metastatic unresectable gastroesophageal or 
gastric adenocarcinoma found no difference compared 
to FOLFOX with placebo for median progression free 
survival (6.4 vs. 6.7 months) or overall survival 11.7 vs. 
11.5 months (46). Of note, this trial had a relatively high 
proportion of esophageal adenocarcinomas in each arm 
(46% in the ramucirumab and FOLFOX group and 49% 
in the FOLFOX/placebo group), and was conducted at 
centers in the United States only. While the progression 
free survival rate was significantly higher at 3 months for 
the ramucirumab and FOLFOX patients (89% vs. 75%, 
P=0.02), this did not persist at 6, 9, or 12 months. A phase 
III randomized trial (RAINFALL) is currently in progress 
to assess ramucirumab as a first-line agent with cisplatin 
and capecitabine or 5-FU in HER2 negative metastatic 
gastroesophageal or gastric adenocarcinoma patients at over 
130 centers globally (47).
Apatinib
The most recently assessed VEGF inhibitor for gastric 
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malignancy is apatinib, a tyrosine kinase inhibitor that 
demonstrates strong affinity and selectivity for VEGFR-2. 
A phase II trial of apatinib for advanced or metastatic 
esophagogastric or gastric adenocarcinoma refractory to 
at least two chemotherapeutic agents (including platinum 
and fluoropyrimidine agents) demonstrated improvements 
in both median overall survival (4.8 vs. 2.5 months in the 
placebo arm) and progression free survival (3.7 vs. 1.4 months 
respectively) (48). Based on these promising results from 
the phase II study, once daily oral dosing of apatinib (with 
a treatment cycle of 28 days) was selected for comparison 
to placebo in a multicenter randomized controlled trial at 
over 30 centers in China (49). Again, advanced or metastatic 
gastric adenocarcinoma patients in the apatinib arm 
experienced improved median overall survival compared 
to placebo (6.5 vs. 4.7 months) and longer progression free 
survival (2.6 vs. 1.8 months, respectively). Apatinib was 
generally well tolerated in this trial, with 8.5% experiencing 
grade 3 or 4 hand-foot skin reaction, 4.5% grade 3 or 4 
hypertension, and 2.3% grade 3 or 4 proteinuria. At this 
time, apatinib is not approved for use in the U.S.
c-Met Targeted Therapy
c-Met (mesenchymal-epithelial transition factor) is a 
transmembrane tyrosine kinase receptor that is activated 
upon binding the hepatocyte growth factor (HGF) with 
overexpression being associated with poorer survival in 
gastric cancer as well as other malignancies (50). While 
c-Met overexpression has been documented with relatively 
low rates among gastric malignancies (approximately 
10%), this value is remarkably high among esophageal 
squamous cell cancers at almost 70% (51). Previous work 
has shown that esophageal squamous cell tumors with c-Met 
overexpression demonstrate a correlation with increasing 
tumor depth and pathologic stage, and is independently 
associated with poorer 5-year overall survival (51). 
Foretinib
Additionally, relevant to esophageal and gastric malignancies 
is the finding that activation of c-Met pathways may occur 
in the setting of HER2 targeted therapy. Specifically, 
description of c-Met/HGF activation causing escape of 
tumor cells from lapatinib-induced growth inhibition in 
HER2 amplified gastric cancer cells has been reported (52). 
Similarly, c-Met amplification has been associated with 
resistance to EGFR therapy (erlotinib, gefitinib) in lung 
cancer patients (53). As such, potential c-Met inhibitors have 
been a focus of active research. One such development has 
been foretinib, an oral multikinase inhibitor (with targets 
including c-Met, VEGFR, RON, and AXL), that has had 
promising results in reversing the HGF induced escape 
mechanisms from lapatinib and erlotinib therapy (54). 
Recently, a phase II trial did not show any efficacy in overall 
response rate, progression free survival, or overall survival for 
foretinib alone among poorly differentiated locally advanced 
or metastatic gastric adenocarcinoma patients, but has not yet 
been evaluated in conjunction with HER2 targeted therapy, 
or among esophageal squamous cell patients, where the 
prevalence of c-Met overexpression is higher (55). 
Onartuzumab 
Results of a phase II trial of onartuzumab, a monoclonal 
antibody with activity against c-Met in conjunction 
with FOLFOX6 for advanced gastroesophageal cancer 
demonstrated no difference in the primary end-point 
(progression-free survival) (56). Of note, approximately 30% 
of patients in each arm were c-Met positive patients (≥50% of 
tumor with moderate to strong intensity staining on IHC), and 
even among this enriched subgroup, no benefit was detected. 
In a phase III trial with metastatic HER2 negative, c-Met 
positive gastroesophageal cancer patients again comparing 
first line FOLFOX6 to FOLFOX6 with onartuzumab 
(METGastric), no difference in overall survival was detected 
for the enrolled group or among strongly (2+, 3+) c-MET 
positive patients (57). Exploratory subgroup analyses did 
show improved overall survival among non-Asian patients 
and in patients without gastrectomy, with any c-MET status. 
Rilotumumab
In an alternative effort to interfere with the c-MET 
HGF pathway, rilotumumab was developed as a human 
monoclonal antibody with high affinity for HGF, thereby 
preventing it from binding to the c-MET receptor. A phase 
II trial examining the use of rilotumumab with epirubicin, 
cisplatin, and capecitabine for first-line treatment of 
locally advanced or metastatic gastroesophageal or gastric 
adenocarcinoma, suggested an improvement in progression 
free survival events for patients receiving rilotumumab 
versus placebo (58). Based on these findings, a phase III 
trial was developed (RILOMET-1), but was stopped early 
secondary to increased mortality in in the rilotumumab 
arm (59). Patients in the rilotumumab arm had poorer 
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overall survival (9.6 vs. 11.5 months, P=0.016) and objective 
response rate (30% vs. 39.2%, P=0.03). On subgroup 
analysis, rilotumumab was still not associated with any 
improvement in survival, even for patients with ≥1+ c-MET 
expression. With these findings, the use of rilotumumab in 
other clinical trials was halted as well. 
Mechanistic target of rapamycin (mTOR) 
targeted therapy
mTOR is a protein kinase with an impressive array of cellular 
functions when activated, including cell proliferation, growth, 
transcription, and protein synthesis. Pathologic comparisons 
of gastric adenocarcinoma to normal gastric mucosa have 
demonstrated increased expression of mTOR in tumor 
samples, as well as upstream proteins known to activate 
mTOR, such as PI3K and AKT (60). PTEN, a known 
regulator of mTOR activation (by inhibiting the PI3K/
AKT/mTOR pathway) has been found to be significantly 
lower in gastric tumor samples. Further work established the 
correlation between increased cytoplasmic mTOR expression 
and depth of gastric adenocarcinoma invasion, lymph node 
involvement, more advanced tumor stage, poorer relapse-
free survival and overall survival (61). Alternatively, nuclear 
mTOR expression was negatively correlated with tumor 
invasiveness and poorer survival outcomes. 
Everolimus
Everolimus has long been used as an oral mTOR inhibitor 
in solid organ transplant patients as an immunosuppressive 
agent, but began to gather attention as a novel agent 
for renal cell carcinoma, pancreatic neuroendocrine 
tumors, and select breast cancer patients (ER/PR positive, 
HER2 negative). A phase II study of everolimus (with 
standard dosing of 10 mg daily) as a second-line agent for 
patients with advanced gastric adenocarcinoma who had 
demonstrated progression on prior chemotherapy showed 
a promising disease control rate of 56% and median 
progression-free survival of 2.7 months (62). However, a 
phase III trial of everolimus in the same patient population 
(GRANITE-1) approached, but did not reach significance 
in median overall survival between the everolimus arm and 
the placebo group (5.4 vs. 4.3 months, P=0.12) (63).
Immunotherapy targets
With breakthrough agents in the realm of immunomodulation 
therapy for melanoma, lymphoma and other malignancies, 
attention has begun to shift to the possible role and efficacy 
of immune checkpoint inhibitors for gastrointestinal 
cancers. One approach that is currently at the forefront of 
such research is blockading the interaction between T-cells 
and tumor cells through programmed death-1 receptor-
ligand binding. While this interaction inhibits T-cell 
costimulation and facilitates evasion of the tumor cell from 
the immune system, targeted inhibitors can block the binding 
of the cytotoxic T-cell receptor to the tumor cell programmed 
death-1 ligand (PDL1) (64). Anti-PD1 therapy has already 
demonstrated impressive and durable improvements in 
clinical responses in patients with melanoma, non-small cell 
lung cancer, and renal cell carcinoma (65-67). Features that 
make gastroesophageal cancers attractive for this type of 
checkpoint therapy include high rates of somatic mutations 
as well as the identification of gastric cancer subtypes with 
high PD-L1 expression (68,69).
Pembrolizumab 
Previous analysis of tumor samples from stage II and 
III gastric cancer patients has demonstrated that PDL1 
overexpression was observed in approximately 30% of 
patients, and was independently associated with poorer 
overall survival, suggesting that this may be an actionable 
target for subgroups of patients with these tumors (70). 
The KEYNOTE-012 phase Ib trial was a multicenter 
study that evaluated pembrolizumab, a humanized antibody 
against PD-1, in patients with a variety of malignancies 
including advanced gastric, urothelial, head and neck, and 
triple negative breast cancer (71). Patients were eligible 
for entry into the gastric cancer cohort if they were 
determined to have PD-L1 positive recurrent or metastatic 
adenocarcinoma of the gastroesophageal junction or stomach 
(after any therapy type, but excluding previous treatment 
with other immune checkpoint inhibitors), and were given 
pembrolizumab every 2 weeks for 24 months or until disease 
progression, death, toxicity, or study withdrawal. PDL1 
positivity was initially assessed by membrane staining in at 
least 1% of cells in a section of archived tumor cells and then 
re-evaluated with a prototype immunohistochemistry assay 
that assigned PDL1 density scores to both the tumor cells as 
well as mononuclear inflammatory cells. Of the 162 patients 
screened, 40% demonstrated PD-L1 positivity (72). 
Of the 36 patients in the gastric malignancy cohort of 
the KEYNOTE-012 trial that were able to be evaluated, 
22% (95% CI, 10–39%) demonstrated partial response 
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to pembrolizumab with a median duration of response of 
40 weeks, with 4 patients continuing to have no evidence 
of disease progression. No patients in the study achieved 
a complete response rate. This response rate was similar 
between Asian institutions and other geographic centers. 
Of note, patients with a higher mononuclear inflammatory 
PDL1 cell density score experienced a higher partial 
response rate (score 3: 44%) than patients with a high tumor 
PDL1 proportion (50–100%: 33%). No treatment-related 
treatment discontinuation or deaths occurred, and only 
13% of patients experienced grade 3 (fatigue, pemphigoid, 
hypothyroidism, peripheral neuropathy) or 4 (pneumonitis) 
complications. Median overall survival was 11.4 months 
(95% CI, 5.7–not reached). Interestingly, 8 patient biopsies 
assessed at the time of data completion had essentially 
negative PDL1 status (mononuclear inflammatory PDL1 
cell density score of 1 or less and tumor PDL1 proportion 
of 0), possibly suggesting changes in PDL1 expression 
following treatment with pembrolizumab or heterogeneity 
of the gastric tumors (73).
Recently, pembrolizumab was also evaluated in esophageal 
cancer (squamous cell or adenocarcinoma histology) as a 
phase Ib trial in patients with a similar PD-L1 positivity and 
treatment regimen as described in KEYNOTE-012 (74). 
In this trial, 41% of enrolled esophageal cancer patients 
demonstrated PD-L1 positivity, with a patient population 
that skewed to squamous cell (77%). Of note, the majority 
(87%) of patients had received two or more previous types of 
systemic therapy prior to participation in the study. Objective 
response rate in this trial was 23%, with no drug related 
adverse events greater than grade 3. Currently, the phase II 
KEYNOTE-180 study is also evaluating pembrolizumab 
in advanced or metastatic esophageal adenocarcinoma or 
squamous cell cancer that has progressed on two prior 
agents (including trastuzumab if HER2 positive) (75).
Nivolumab
Nivolumab, another human monoclonal antibody targeted 
against PD-1 with efficacy demonstrated in various 
malignancies including melanoma and non-small cell lung 
cancer has also been considered for upper gastrointestinal 
tumors. Reports from a phase I/II trial (part of the 
CheckMate-032 study) with 59 advanced or metastatic 
gastroesophageal or gastric cancer patients treated 
with single agent nivolumab demonstrated an objective 
response rate of 12%, with one complete response and 
6 partial responses (76). Of note, 39% of tumor samples 
were classified as PD-L1 positive, with a higher objective 
response rate (18%). About 21% of patients were noted to 
have stable disease. Given these findings, it is feasible that 
nivolumab may be considered for further evaluation in a 
randomized controlled trial. 
Conclusions and future directions
While advanced esophageal, esophagogastric, and gastric 
malignancies continue to have a prominent global presence 
with poor 5-year survival outcomes, significant gains 
are starting to be made with the use of targeted biologic 
therapies. In the near future, the evaluation and clinical use 
of these agents will be greatly assisted by comprehensive 
characterizations and subclassifications of gastric and 
related GI malignancies. This massive effort is already 
underway in projects such as The Cancer Genome Atlas 
Research Network (TCGA) which is working to organize 
gastric malignancies into four subtypes each with a distinct 
and relatively predictable mutation profiles: Ebstein-Barr 
positive tumors, genomically stable tumors, tumors with 
microsatellite instability, and tumors with chromosomal 
instability (77). 
While not all agents (EGFR inhibitors) have demonstrated 
the same efficacy in esophageal and gastric malignancies 
that they have accomplished for other tumor types, others 
are now employed as recommended agents in progressive or 
refractory disease (trastuzumab and ramucirumab).  Others, 
such as lapatinib, onartuzumab, and bevacizumab, may 
demonstrate improved efficacy among specific geographic 
populations and warrant further tailored investigation. 
Furthermore, the potential agents for immunomodulation 
therapy continue to expand and pose exciting developments 
for esophageal and gastric malignancies.  While the pace 
of biologic therapies, including immunotherapy agents, in 
phase I, II, and III trials continue at a fervent pace, important 
components to contextualize these studies will include the 
role of potential biomarkers to guide tailored therapy, as 
well as decision and cost-effectiveness analyses to assist in 
determining which agents will impart the most substantial 
and meaningful benefits.
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